Close menu

GeNeuro’s ProTEct-MS Phase 2 trial data, presented at the ECTRIMS 2022 Congress in Amsterdam, confirms synergistic neuroprotective potential of temelimab in MS


▪ Excellent safety profile and tolerability of higher doses of temelimab
▪ Synergistic potential to treat neurodegeneration in addition to high-efficacy anti-inflammatory therapy in multiple sclerosis
▪ Exploratory CSF biomarkers confirm MRI efficacy observations


Read the press release

More information